Ipratropium Bromide Dosing for Bronchitis
Dosing Guidelines by Administration Route
- For children under 12 years, the recommended dose is 0.25-0.5 mg every 20 minutes for 3 doses, then as needed, according to Praxis Medical Insights 1
- For adults, the recommended dose using a Metered Dose Inhaler (MDI) is 2 puffs (36 mcg) four times daily on a regular schedule, according to Praxis Medical Insights 2
- During acute exacerbations, 8 inhalations every 20 minutes as needed up to 3 hours is recommended, according to Praxis Medical Insights 3
- Each puff contains 18 mcg of ipratropium bromide, as stated by Praxis Medical Insights 3
Combination Therapy with Albuterol
- For adults, nebulized combination therapy with 3 mL (containing 0.5 mg ipratropium bromide and 2.5 mg albuterol) every 20 minutes for 3 doses, then as needed, is recommended by Praxis Medical Insights 3
- For children, nebulized combination therapy with 1.5 mL every 20 minutes for 3 doses, then as needed, is recommended by Praxis Medical Insights 1 and 3
Clinical Considerations
- Multiple doses in the emergency department setting provide additive benefit to short-acting beta-agonists (SABAs), as reported in the Journal of Allergy and Clinical Immunology 4
Potential Adverse Effects
- Side effects are generally mild and include drying of mouth and respiratory secretions, according to the Journal of Allergy and Clinical Immunology 4
Common Pitfalls to Avoid
- Ensure proper inhaler technique to maximize drug delivery to the lungs, as advised by Praxis Medical Insights 2
- For MDI administration in children under 4 years, use with a spacer chamber and face mask for optimal delivery, according to Praxis Medical Insights 3
Ipratropium Bromide for Bronchitis Management
Combination Therapy and Guidelines
- The American College of Chest Physicians (ACCP) recommends ipratropium bromide as the only inhaled anticholinergic for cough suppression in chronic bronchitis, with a Grade A recommendation (fair evidence, substantial benefit) 5, 6
- Ipratropium can be safely combined with beta-agonists for enhanced bronchodilation in bronchitis, according to the ACCP guidelines 5, 6
- The ACCP guidelines provide a Grade A recommendation (fair evidence, substantial benefit) for ipratropium as the sole recommended inhaled anticholinergic for cough due to URI or chronic bronchitis 5, 6